Emil D Kakkis sold $1.2M of RARE
President & CEO at Ultragenyx Pharmaceutical Inc.. 54,404 shares at an average of $22.80, traded Mar 2, 2026, filed Mar 3, 2026.
Score components
- +25RoleCEO
- +25Trade size$1.2M at market
- 0Share of holdings soldSold 7.6% of holdings
- +15Cluster7 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +1.7%, 3m -1.3%, 6m +16.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-089278, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 1, 2026 | AGrant or award Common Stock | +71,177 | $0.00 | $0 | 712,908 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock | -54,404 | $22.80 | $1.2M | 658,994 | Mar 3, 2026 |
Related signals
Other insiders at Ultragenyx Pharmaceutical Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Ultragenyx Pharmaceutical Inc. | Theodore Alan Huizenga SVP, Chief Accounting Officer | $17k 1,283 shares | -2% | |
| 15Weak | RAREsell Ultragenyx Pharmaceutical Inc. | Theodore Alan Huizenga SVP, Chief Accounting Officer | $2,252 161 shares | -0% | |
| 20Weak | Ultragenyx Pharmaceutical Inc. | Howard Horn Chief Financial Officer | $117k 4,696 shares | -5% | |
| 9Weak | Ultragenyx Pharmaceutical Inc. | Karah Herdman Parschauer EVP and Chief Legal Officer | $47k 1,900 shares | -2% | |
| 13Weak | Ultragenyx Pharmaceutical Inc. | Howard Horn Chief Financial Officer | $156k 4,698 shares | -4% | |
| 16Weak | Ultragenyx Pharmaceutical Inc. | Karah Herdman Parschauer EVP and Chief Legal Officer | $47k 1,899 shares | -2% | |
| 37Weak | Ultragenyx Pharmaceutical Inc. | Corazon (Corsee) D. Sanders director | $50k 2,000 shares | -9% | |
| 27Weak | Ultragenyx Pharmaceutical Inc. | Howard Horn Chief Financial Officer | $111k 4,653 shares | -4% | |
| 26Weak | Ultragenyx Pharmaceutical Inc. | Shehnaaz Suliman director | $144k 5,740 shares | -17% | |
| 30Weak | Ultragenyx Pharmaceutical Inc. | Eric Crombez EVP and Chief Medical Officer | $8,586 344 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.